🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT04839523
Active, not recruiting Not applicable

Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

NCT04839523 · tracked via the Priya Life Science USA tracker
Sponsor
Molnlycke Health Care AB
Phase
Not applicable
Started
2021-03-10
Last updated
2024-11-12

Condition(s) studied

Partial-thickness Burn

Investigational drug(s) / intervention(s)

ExufiberExufiber Ag+

Exufiber: A sterile nonwoven wound dressing made from highly absorbent PVA fibers.

Exufiber Ag+: A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.

Study summary

This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit.

Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.

Eligibility

Sex
ALL
Min age
4 Weeks
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Signed informed consent 2. Burn of thermal origin 3. Patients presenting with partial thickness burns covering \< 5% TBSA for study treatment 4. TBSA covered with any burn type is ≤15%, with a maximum of 10% being full thickness burns 5. Clean wounds with ≤10% necrotic tissue 6. Patients presenting with moderate to high exuding wounds 7. Serous or Serosanguinous exudate 8. Patient is not contraindicated for the dressing to which he/she is assigned Exclusion Criteria: 1. Electrical Burns 2. Chemical Burns including acidic or basic sources 3. Ionizing radiation injuries 4. Dry wounds 5. Neonates 6. Patients with delayed presentation for burn care (\>72 hours from time of injury) 7. Before entry into the study, treatment to the study wound included an active agent that would confound study results, as determined by the Investigator 8. Burns under study treatment transitioning to full thickness, or deep partial thickness burns requiring surgical treatment 9. Clinically infected burn 10. Patients with insulin dependent diabetes mellitus 11. Patients treated with systemic glucocorticosteroids, except patients taking occasional doses or doses less than 10mg prednisolone per day or equivalent 12. Patients who have used immunosuppressive agents, radiation or chemotherapy within past 30 days 13. Known allergy/hypersensitivity to any of the components of the investigation products 14. History of comorbid conditions or diagnoses associated with higher risk of infection as determined by the Investigator 15. Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer, severe anemia) 16. Patients that are not expected to comply with the investigation due to physical and/or mental conditions 17. Pregnancy 18. Participation in other clinical investigation(s) within 1 month prior to start of the investigation 19. Previously enrolled in this investigation

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Arizona Burn Center, Valleywise Health Phoenix Arizona
Keck Medical Center of USC Los Angeles California
MedStar Health Research Institute Washington D.C. District of Columbia
University of South Florida-Tampa General Hospital Tampa Florida
Massachusetts General Hospital Boston Massachusetts
Drexel Univerisity Philadelphia Pennsylvania

More Molnlycke Health Care AB trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04839523 on ClinicalTrials.gov ↗ ← All trials in the USA